Glenmark Pharmaceuticals Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

The product has been determined to be bioequivalent to Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC), developed by Alcon Laboratories, Inc. With this approval, Glenmark Therapeutics Inc., USA, will distribute the product in the US market, further expanding the company?s ophthalmic portfolio.

Olopatadine ophthalmic (eye) drops are used to treat itching of the eye caused by a condition known as allergic conjunctivitis (pink eye). This medicine is also used to treat eye itching or redness caused by pollen, ragweed, grass, animal hair, or dander.

According to Nielsen syndicated data for the 52-week period ending 22 February 2025, the Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC), achieved annual sales of approximately $50.7 million.

Commenting on the launch, Marc Kikuchi, president & business head of North America, said, ?We are pleased to continue expanding our OTC ophthalmic portfolio. The addition of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%, highlights our commitment to meeting market needs and providing quality over-the-counter solutions for our customers.?

Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries.

On a consolidated basis, the company reported a net profit of Rs 348 crore in Q3 FY25 compared with a net loss of Rs 449.6 crore in Q3 FY24. Revenue from operations surged 35.1% YoY to Rs 3,387.6 crore in the quarter ended 31 December 2024.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).

These medications are designed to improve glycemic control in adults with T2DM while also reducing cardiovascular outcomes in T2DM patients with CV risk. 

Empagliflozin is a globally established treatment for HF, T2DM and T2DM with established cardiovascular disease (CVD), offering multiple benefits like cardiovascular and renal safety. The EMPA-REG clinical trial demonstrated a 14% reduction in major cardiovascular events, positioning Empagliflozin as a significant advancement in T2DM patients with high CV risks.

Powered by Capital Market - Live News

The drug will be marketed under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).

Empagliflozin is a globally established treatment for heart failure and diabetes, offering multiple benefits, including cardiovascular and renal safety.

Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals, said, “Glenmark has a strong legacy of introducing innovative and accessible treatments for cardiometabolic care in India. The launch of the Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage T2DM with established CVD more effectively.”

Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries.

On a consolidated basis, the company reported a net profit of Rs 348 crore in Q3 FY25 compared with a net loss of Rs 449.6 crore in Q3 FY24. Revenue from operations surged 35.1% YoY to Rs 3,387.6 crore in the quarter ended 31 December 2024.

The scrip fell 1.38% to currently trade at Rs 1,381.15 on the BSE.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).

These medications are designed to improve glycemic control in adults with T2DM while also reducing cardiovascular outcomes in T2DM patients with CV risk. 

Empagliflozin is a globally established treatment for HF, T2DM and T2DM with established cardiovascular disease (CVD), offering multiple benefits like cardiovascular and renal safety. The EMPA-REG clinical trial demonstrated a 14% reduction in major cardiovascular events, positioning Empagliflozin as a significant advancement in T2DM patients with high CV risks.

Powered by Capital Market - Live News

The drug will be marketed under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).

Empagliflozin is a globally established treatment for heart failure and diabetes, offering multiple benefits, including cardiovascular and renal safety.

Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals, said, “Glenmark has a strong legacy of introducing innovative and accessible treatments for cardiometabolic care in India. The launch of the Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage T2DM with established CVD more effectively.”

Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries.

On a consolidated basis, the company reported a net profit of Rs 348 crore in Q3 FY25 compared with a net loss of Rs 449.6 crore in Q3 FY24. Revenue from operations surged 35.1% YoY to Rs 3,387.6 crore in the quarter ended 31 December 2024.

The scrip fell 1.38% to currently trade at Rs 1,381.15 on the BSE.

Powered by Capital Market - Live News

The aforementioned product is a generic equivalent of ‘MiraLAX Powder for Solution’ of Bayer HealthCare LLC.

Polyethylene Glycol is an osmotic laxative. It prevents and treats occasional constipation.

According to Nielsen syndicated data for the latest 52 weeks’ period ending 22 February 2025, the MiraLAX Powder for Solution OTC market achieved annual sales of approximately $555.7 million.

Marc Kikuchi, president & business head, North America, said: We are excited to announce the launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful, addressing the growing demand for a new supplier in this category.

This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers.

Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries.

On a consolidated basis, the company reported a net profit of Rs 348 crore in Q3 FY25 compared with a net loss of Rs 449.6 crore in Q3 FY24. Revenue from operations surged 35.1% YoY to Rs 3,387.6 crore in the quarter ended 31 December 2024.

The scrip shed 0.31% to currently trade at Rs 1402.20 on the BSE.

Powered by Capital Market - Live News

The product has been determined to be bioequivalent to Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC), developed by Alcon Laboratories, Inc. With this approval, Glenmark Therapeutics Inc., USA, will distribute the product in the US market, further expanding the company?s ophthalmic portfolio.

Olopatadine ophthalmic (eye) drops are used to treat itching of the eye caused by a condition known as allergic conjunctivitis (pink eye). This medicine is also used to treat eye itching or redness caused by pollen, ragweed, grass, animal hair, or dander.

According to Nielsen syndicated data for the 52-week period ending 22 February 2025, the Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC), achieved annual sales of approximately $50.7 million.

Commenting on the launch, Marc Kikuchi, president & business head of North America, said, ?We are pleased to continue expanding our OTC ophthalmic portfolio. The addition of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%, highlights our commitment to meeting market needs and providing quality over-the-counter solutions for our customers.?

Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries.

On a consolidated basis, the company reported a net profit of Rs 348 crore in Q3 FY25 compared with a net loss of Rs 449.6 crore in Q3 FY24. Revenue from operations surged 35.1% YoY to Rs 3,387.6 crore in the quarter ended 31 December 2024.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).

These medications are designed to improve glycemic control in adults with T2DM while also reducing cardiovascular outcomes in T2DM patients with CV risk. 

Empagliflozin is a globally established treatment for HF, T2DM and T2DM with established cardiovascular disease (CVD), offering multiple benefits like cardiovascular and renal safety. The EMPA-REG clinical trial demonstrated a 14% reduction in major cardiovascular events, positioning Empagliflozin as a significant advancement in T2DM patients with high CV risks.

Powered by Capital Market - Live News

The drug will be marketed under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).

Empagliflozin is a globally established treatment for heart failure and diabetes, offering multiple benefits, including cardiovascular and renal safety.

Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals, said, “Glenmark has a strong legacy of introducing innovative and accessible treatments for cardiometabolic care in India. The launch of the Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage T2DM with established CVD more effectively.”

Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries.

On a consolidated basis, the company reported a net profit of Rs 348 crore in Q3 FY25 compared with a net loss of Rs 449.6 crore in Q3 FY24. Revenue from operations surged 35.1% YoY to Rs 3,387.6 crore in the quarter ended 31 December 2024.

The scrip fell 1.38% to currently trade at Rs 1,381.15 on the BSE.

Powered by Capital Market - Live News

Glenmark Pharmaceuticals has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).

These medications are designed to improve glycemic control in adults with T2DM while also reducing cardiovascular outcomes in T2DM patients with CV risk. 

Empagliflozin is a globally established treatment for HF, T2DM and T2DM with established cardiovascular disease (CVD), offering multiple benefits like cardiovascular and renal safety. The EMPA-REG clinical trial demonstrated a 14% reduction in major cardiovascular events, positioning Empagliflozin as a significant advancement in T2DM patients with high CV risks.

Powered by Capital Market - Live News

The drug will be marketed under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)—Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg).

Empagliflozin is a globally established treatment for heart failure and diabetes, offering multiple benefits, including cardiovascular and renal safety.

Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals, said, “Glenmark has a strong legacy of introducing innovative and accessible treatments for cardiometabolic care in India. The launch of the Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage T2DM with established CVD more effectively.”

Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries.

On a consolidated basis, the company reported a net profit of Rs 348 crore in Q3 FY25 compared with a net loss of Rs 449.6 crore in Q3 FY24. Revenue from operations surged 35.1% YoY to Rs 3,387.6 crore in the quarter ended 31 December 2024.

The scrip fell 1.38% to currently trade at Rs 1,381.15 on the BSE.

Powered by Capital Market - Live News

The aforementioned product is a generic equivalent of ‘MiraLAX Powder for Solution’ of Bayer HealthCare LLC.

Polyethylene Glycol is an osmotic laxative. It prevents and treats occasional constipation.

According to Nielsen syndicated data for the latest 52 weeks’ period ending 22 February 2025, the MiraLAX Powder for Solution OTC market achieved annual sales of approximately $555.7 million.

Marc Kikuchi, president & business head, North America, said: We are excited to announce the launch of Polyethylene Glycol 3350, Powder for Solution, 17 grams/capful, addressing the growing demand for a new supplier in this category.

This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers.

Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries.

On a consolidated basis, the company reported a net profit of Rs 348 crore in Q3 FY25 compared with a net loss of Rs 449.6 crore in Q3 FY24. Revenue from operations surged 35.1% YoY to Rs 3,387.6 crore in the quarter ended 31 December 2024.

The scrip shed 0.31% to currently trade at Rs 1402.20 on the BSE.

Powered by Capital Market - Live News